Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2001

View Archived Issues

Management of focal spasticity is latest indication granted for Botox in Canada

GSK's Trizivir receives Health Canada approval

Genta to test Genasense in combination with docetaxel for treatment of NSCLC

Phase II results presented from AeroDose inhaled insulin study

Myriad Genetics reviews fiscal Q1 progress

Safety of AVI-4557 confirmed in phase I clinical trial

BioMarin/Ibex enzyme acquisition completed

Replicon receives grant for development of brain tumor therapies

New phase II trial of Mylovenge in conjunction with thalidomide

Wyeth Lederle Vaccines and RIVM collaborate on meningitis vaccine development

Quest Diagnostics, exclusive distributor of Vasogen's immune modulation therapy

Aripiprazole submitted for FDA review as a treatment for schizophrenia

Alteon commences phase I testing of ALT-711 in ESRD patients undergoing peritoneal dialysis

AMD-3100 rapidly mobilizes stem cells in phase I trial

Antisoma sees further progress on all fronts during the first quarter

Predictable, dose- and time-independent PK for Arixtra in young and elderly subjects

Data presented at Chest 2001 support use of tiotropium in COPD maintenance therapy

Status of Tibotec-Virco next-generation anti-HIV drugs updated in Athens

European Commission issues approval for Glivec in Bcr-Abl-positive CML

Sulfonamide glutamate receptor potentiators useful in cognitive impairment

New imidazoles for histamine H3-mediated disorders jointly identified by European labs

New series of cell adhesion inhibitors and potential uses described by Novartis

Subunit-selective GABA-A receptor agonists in development by Sanofi-Synthelabo

Wilex and Max Planck design new selective uPA inhibitors for cancer therapy

Motilin antagonists identified at Ortho-McNeil

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...